Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis.
Bioinformatics reveal macrophages marker genes signature in breast cancer to predict prognosis.
复制标题
生物信息学揭示乳腺癌中巨噬细胞标记基因特征以预测预后
DOI：
10.1080/07853890.2021.1914343
复制
发表时间：
2021-12
影响因子：
4.4
通讯作者：
Liu Y
中科院分区：
文献类型：
--
作者：
Li Y;Zhao X;Liu Q;Liu Y
摘要背景乳腺癌是全球妇女癌症死亡的主要原因。免疫治疗已成为治疗乳腺癌的一种有前途的手段。巨噬细胞作为乳腺癌免疫微环境的组成部分，在肿瘤的发生发展和治疗中发挥着复杂的作用。本研究旨在开发一种预测巨噬细胞标志基因签名（MMGS）。方法应用单细胞RNA序列分析技术，筛选乳腺癌巨噬细胞标志基因。使用TCGA数据库构建MMGS模型作为训练队列，使用GSE96058数据集验证MMGS模型作为验证队列。结果MMGS模型中包含的基因有：SERPINA1、CD74、STX11、ADAM 9、CD24、NFKBIA、PGK1。MMGS风险评分按患者的总生存期分层，将其分为高风险组和低风险组。在多变量分析中，MMGS风险评分在训练和验证队列中校正经典临床因素后仍然是独立的预后因素。此外，激素受体阴性和人表皮生长因子受体2（HER2）阳性患者的风险评分较高。MMGS对激素受体阳性和HER2阴性亚组的高危和低危组有较好的区分能力。结论MMGS为乳腺癌患者免疫细胞标志基因的预后提供了新的认识，可为乳腺癌患者的免疫治疗决策提供参考。
Abstract Background Breast cancer is a pivotal cause of global women cancer death. Immunotherapy has become a promising means to cure breast cancer. As constitutes of immune microenvironment of breast cancer, macrophages exert complicated functions in the tumour development and treatment. This study aims to develop a prognostic macrophage marker genes signature (MMGS). Methods Single cell RNA sequence data analysis was performed to identify macrophage marker genes in breast cancer. TCGA database was used to construct MMGS model as a training cohort, and GSE96058 dataset was used to validate the MMGS as a validation cohort. Results Genes included in the MMGS model were: SERPINA1, CD74, STX11, ADAM9, CD24, NFKBIA, PGK1. MMGS risk score stratified by overall survival of patients divided them into high- and low-risk groups. And MMGS risk score remained independent prognostic factor in multivariate analysis after adjusting for classical clinical factors in both training and validation cohorts. Besides, hormone receptors negative and human epidermal growth factor receptor 2 (HER2) positive patients had higher risk score. MMGS showed better distinguishing capability between high-risk and low-risk groups in hormone receptor positive and HER2 negative subgroup. Conclusion MMGS provides a new understanding of immune cell marker genes in breast cancer prognosis and may offer reference for immunotherapy decision for breast cancer patients.